Medicis Pharmaceutical Inactive 10-K2010 FY Annual report

Filed: 1 Mar 11, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: Acella, acknowledged, admitted, Affordability, Affordable, AmerisourceBergen, Anacor, Antonio, art, Aurobindo, behavior, benzoate, bioavailable, biosimilar, boron, BPCIA, breached, capacity, chemistry, choose, cited, Cleansing, Coalition, Columbia, contributorily, correctly, County, departure, desist, discovery, distracting, distraction, divestiture, doughnut, DYSPORT®and, DYSPORT®Challenge, DYSPORT®were, endorsed, enrollment, equitable, excise, excused, exerted, expenditure, exploration, explore, faith, FCPA, feasible, Fed, Fibrocell, fiduciary, filer, footage, foregoing, futile, gap, gave, Genzyme, HIPAA, hole, identical, inpatient, interactive, internationally, landscape, Language, licensure, long, lump, mandated, Maricopa, Markman, molecule, monthly, nationwide, NDAA, noninfringement, Nycomed, occasion, Oct, opposed, opposing, oversee, owed, partner, passed, phenylacetate, phenylbutyrate, PHS, physical, pioneer, platform, Portability, Poverty, Powder, pre, privacy, proceed, prorated, prudent, quantity, rationalize, referral, Reg, Reissuance, repatriation, restraining, resubmitted, retroactive, robust, San, SCT, searchable, Sense, Seton, Similarly, software, solid, Southern, Street, stringent, sublicense, subtracting, sulfacetaminde, Supp, tariff, Taro, TMA, unrest, VANOS®prior, VELTIN, VII, waived, Wall, XBRL, XC, Xeomin

Removed: Abbott, administering, Ansata, APB, bacteria, banker, behave, BioForm, Bulletin, complimentary, confirm, Deficit, Dow, eradicating, expensing, FDAMA, FIN, glycolic, GMHB, incident, integration, lactate, mode, NDMA, Northern, notwithstanding, ointment, OMNICEF, pad, parent, promoter, prygocki, rejection, resistance, SAB, sr, subprime, tentative, Treasurer, trustee, tumor, undertaken, UV, Vice, Wiech, word, zinc

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Medicis Pharmaceutical similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Medicis Pharmaceutical Corporation (the “Company”) on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard D. Peterson, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)		The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)		The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented.



	/s/ RICHARD D. PETERSON
	Richard D. Peterson
	Executive Vice President, Chief Financial Officer and Treasurer March 1, 2011

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Medicis Pharmaceutical Corporation and will be retained by Medicis Pharmaceutical Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.